Created by FotoFinder Systems, Moleanalyzer pro is a portal that lets physicians confirm their skin cancer diagnosis using evaluation techniques, combining specialist expertise with AI and including the option of receiving a second opinion from international skin cancer experts. FotoFinder Systems Global Brand Director Kathrin Niemela told HITNA that the technology aims to aid skin cancer diagnoses. According to the Cancer Council Australia, every year skin cancers account for around 80 per cent of all newly diagnosed cancers in Australia, with GPs seeing more than a million patients per year for skin cancer. In addition, the Australian Government identified that there were 14,320 new cases of melanoma skin cancer diagnosed in 2018, accounting for 10.4 per cent of all new cancer cases diagnosed. "The earlier skin cancer is detected, the better the prognosis. The leisure behaviour of sunbathing in many parts of the world makes early detection of skin cancer more important worldwide," Niemela said.
Imagine a world where you can detect issues early and can use that information to make changes that are beneficial for everyone? What if that was possible now? Thanks to Ken Ferry, the CEO of iCAD, there is no need to wonder. Ken and his team have developed innovative technology that detects cancer at an early stage and offers therapy solutions that provide non-invasive treatment for patients. Tamara: Can you share a story that inspired you to get involved in AI? Ken: What inspires and excites me the most about AI is the fact that this innovative technology has the ability to protect and preserve life through the collaboration between technology and medical science.
The UK is about to make a big bet on AI's ability to spot cancer. The Guardian has learned that Prime Minister Theresa May will commit "millions of pounds" in funding for research toward AI that can diagnose cancer and chronic diseases at an early stage. The technology could reduce "avoidable deaths," according to May's prepared speech, and is estimated to save as many as 22,000 lives per year by 2033. It would extend healthy living by another five years as of 2035. There is, however, an important catch.
A town in Japan with high rates of stomach cancer is turning to a sniffer dogs for help. Kaneyama, a town in northeastern Japan with 6,000 residents, has Japan's highest fatality rates stemming from stomach cancer, local reports say. The town is now taking part in a research programme, in which residents' frozen urine samples are sent to the Nippon Medical School, just east of Tokyo. At the school, dogs are trained to sniff out signs of disease. Dogs have some 300 million sensors in their nose, compared to five million in a human.
Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced the discovery of a new molecular signature in blood that can be used for early colorectal cancer detection using its new LITOseek platform. Data explaining the use of next generation sequencing (NGS) and machine learning from the studies leading to this discovery will be presented at the upcoming European Society for Medical Oncology (ESMO) meeting (27th September -1st October, Barcelona, Spain). The company's currently marketed test, Colox, is the first commercially available Immuno-Transcriptomic blood based RT-PCR test on the market for the screening of colon cancer. The data regarding the discovery and development of a new Immuno-Transcriptomic molecular signature test for early colon cancer screening on the LITOseek platform will be presented at ESMO. The data will be presented on September 30, 2019 by our academic partner from The Swiss Institute of Bioinformatics under the title "Discovery of an Immuno-Transcriptomics signature in blood for early colorectal cancer detection" in the Poster Display Session 3 on Biomarkers.